Other studies have also shown that extrahepatic tissue-specific (i.e. muscle- [14] or adipocyte- [15]) PPARγ deletion promotes NAFLD and that TZD-treatment exacerbates fatty liver disease in muscle-specific PPARγ KO mice [14]. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.